## Letermovir

<table>
<thead>
<tr>
<th>Spectrum of Activity*</th>
<th>Cytomegalovirus (CMV)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No</strong> activity against other herpesviruses</td>
<td></td>
</tr>
</tbody>
</table>

### Indications

CMV treatment or secondary prophylaxis (maintenance) in adult allogeneic hematopoietic stem cell transplant patients when ganciclovir or valganciclovir cannot be used.

Letermovir retains activity against virus with mutations at UL54 and UL97 (confer resistance to ganciclovir, foscarnet, cidofovir).

### Not indicated

Herpesviruses besides CMV

### Safety Considerations

- Well tolerated: nausea, vomiting, cough, headache, peripheral edema
- Not recommended for patients with severe liver impairment (Child-Pugh class C)

### Renal Dosing

No dose adjustment

IV: No dosage adjustment necessary; **but** use IV with caution and closely monitor creatinine in patients with CrCl <50 mL/min due to potential accumulation of IV vehicle (hydroxypropyl betadex)

### Other Considerations

Usual dose 480 mg IV/PO once daily, high bioavailability

### CHECK FOR INTERACTIONS

- Letermovir is a moderate inhibitor of CYP3A & CYP2C8
- **Contraindicated** with concomitant use of
  - pimozide (due to risk of QT prolongation and torsades) and ergot alkaloids
  - lovastatin, simvastatin, or atorvastatin due to risk of myopathy or rhabdomyolysis
  - rifampin
- If letervomir is co-administered with cyclosporine, decrease dosage of letervomir to 240mg once daily
- ↑ tacrolimus/sirolimus levels: monitor
- ↑ amiodarone levels, ↓ warfarin levels,
  - ↓ phenytoin, ↓ voriconazole